Ultragenyx Pharmaceutical Inc. settled a suit with the US government for $6 million over allegations it violated the False Claims Act when it paid for free genetic tests that induced prescriptions of the drug Crysvita, which would be reimbursed by Medicare or Medicaid.
Crysvita is used to treat X-linked hypophosphatemia, a rare genetic disorder characterized by low phosphate blood levels that can lead to weak bones. A genetic test is required to confirm the diagnosis and for insurers, including Medicare and Medicaid, to pay for the drug prescription.
AI-powered legal analytics, workflow tools and premium legal & business news.
Log in to keep reading or access research tools.
CINCINNATI (WXIX) - Cincinnati-based The Kroger Co. is under federal investigation for alleged False Claims Act violations in its opioid dispensing practices, according to newly filed court record...